MEMBER'S AREA
GET IN TOUCH
JOIN US!

Mentorship Program

BACK

Welcome to the new ISCBH mentoring initiative!

We listened! The ISCBH new and emerging investigators group has identified the need for mentorship opportunities. We are happy to launch our ISCBH Emerging Investigator Mentorship Program!
 

Aims

  • Create mentor-mentee connections that will lead to fruitful mentor-mentee relationships
  • Encourage a meaningful experience for both mentors and mentees

Our target audience

  • Mentees will be current and newly interested Emerging Investigator members who are also members of the ISCBH .
  • Mentors will all be senior members and leaders within ISCBH.

The process of our mentoring program

  • On receipt of mentee application, we will send two key published papers on the topic of mentorship to the mentee along with a mentee reflection guide.
  • Pairings will be formed by ISCBH co-chairs and first mentor-mentee meeting will be arranged
  • Mentor-mentee will meet for the first time (meeting arranged through ISCBH)
  • Subsequent meetings are encouraged quarterly and these will be arranged by mentees/mentors
  • We will keep track of our pairings with regular surveys to gauge the levels of commitment, perceived benefits and barriers to success.
Apply to be a MENTEE
Apply to be a MENTOR

Marie-Eve
Robinson

EMAIL

Jeanne Franzone

Jeanne
Franzone

EMAIL

ISCBH HOME

Registered Office: Kaiser Josef Straße 9, 6020 Innsbruck, Austria

© 2023 International Society for Children’s Bone Health

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE